Coherus Oncology, Inc.
CHRSNasdaqCIK 1512762HealthcareFiscal year ends Dec 31
All transactions: 4
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2014-11-12 | Lilly Eli & CoFormer 10% Owner | Purchase | 164,963 | $13.50 | $2.2m | Form 4 |
| 2014-11-12 | Lilly Eli & CoFormer 10% Owner | Conversion | 543,101 | not reported | not reported | Form 4 |
| 2014-11-12 | Lilly Eli & CoFormer 10% Owner | Conversion | 2,333,955 | not reported | not reported | Form 4 |
| 2014-11-12 | KKR Biosimilar L.P.10% owner | Conversion | 2,499,499 | not reported | not reported | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 29, 2026, 08:11 ET. Listed shows no prices and gives no investment advice.